10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||||||||||||
| |||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
REGENERON PHARMACEUTICALS, INC. | |||
Ticker: REGN Fiscal Year: 2017 | |||
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME | |||
Period Ending Dec 31, 2017 10-K (Filed: Feb 8, 2018) | |||
| (In Thousands) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | |
| Income Statement [Abstract] | |||
| Revenues: | |||
| Net product sales | $ 3,718,463 | 3,338,390 | 2,689,478 |
| Sanofi collaboration revenue | 877,193 | 658,665 | 758,873 |
| Bayer collaboration revenue | 938,052 | 744,270 | 580,488 |
| Other revenue | 338,519 | 119,102 | 74,889 |
| Total revenues | 5,872,227 | 4,860,427 | 4,103,728 |
| Expenses: | |||
| Research and development | 2,075,142 | 2,052,295 | 1,620,577 |
| Selling, general, and administrative | 1,320,433 | 1,177,697 | 838,526 |
| Cost of goods sold | 202,507 | 194,624 | 241,702 |
| Cost of collaboration and contract manufacturing | 194,554 | 105,070 | 151,007 |
| Total expenses | 3,792,636 | 3,529,686 | 2,851,812 |
| Income from operations | 2,079,591 | 1,330,741 | 1,251,916 |
| Other income (expense): | |||
| Other income (expense), net | 24,039 | 6,269 | (12,578) |
| Interest expense, net | (25,119) | (7,195) | (14,241) |
| Total other income (expense) | (1,080) | (926) | (26,819) |
| Income before income taxes | 2,078,511 | 1,329,815 | 1,225,097 |
| Income tax expense | (880,000) | (434,293) | (589,041) |
| Net income | 1,198,511 | 895,522 | 636,056 |
| Net income per share - basic | 11.27 | 8.55 | 6.17 |
| Net income per share - diluted | 10.34 | 7.70 | 5.52 |
| Weighted average shares outstanding - basic | 106,338 | 104,719 | 103,061 |
| Weighted average shares outstanding - diluted | 115,954 | 116,367 | 115,230 |
| Statements of Comprehensive Income | |||
| Net income | 1,198,511 | 895,522 | 636,056 |
| Other comprehensive income (loss), net of tax: | |||
| Unrealized (loss) gain on marketable securities | 12,715 | (21,412) | (43,679) |
| Unrealized gain on cash flow hedges | 765 | 0 | 0 |
| Comprehensive income | 1,211,991 | 874,110 | 592,377 |
| External Links | |
| REGENERON PHARMACEUTICALS, INC. (REGN) Fiscal Year 2017 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |